Trial Profile
A Phase I and Pharmacokinetic Study to Evaluate Histone Deacetylase Inhibitor, Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Eddingpharm
- 01 Jul 2021 Results assessing the safety, tolerability and pharmacokinetic profile of entinostat alone and in combination with exemestane in Chinese postmenopausal patients with locally advanced or metastatic HR positive / HER2 negative metastatic breast cancer, published in the Targeted Oncology.
- 03 May 2019 Status changed from recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 1 Dec 2019 to 1 Sep 2018.